Table 2.

Comparison of Immune responses that influence VE in RV 144 versus past and ongoing HIV vaccine trials.

Immune response identified as a correlate in RV144	Responses in non-RV144 efficacy trials	Responses in vaccines in current development
Total IgG to V1V2 scaffold	Lower in HVTN 505 compared with RV144	Higher titers in DNA / NYVAC / gp120 than RV144. Correlates of protection in heterologous NHP challenge studies with Ad26/Ad35 and Ad26/MVA studies.
Serum IgA to gp120 (higher IgA = lower VE)	Higher IgA (including IgA to A1ConEnv) in HVTN 505, compared to RV144	Administration of gp120 at onset of priming with NYVAC and DNA/NYVAC markedly lowers serum IgA to gp120 DNA/MVA priming has lower IgA
IgG3 to V1V2	Lower in HVTN 505 and VAX003 than RV144	Under evaluation
ADCC activity	Minimal ADCC in HVTN 505	ADCC correlates with protection in NHP using Ad26 +/− trimeric gp120 High ADCC in DNA/MVA regimen
Tier 1 nAbs	Higher frequency in RV144 compared with HVTN 505	Clade C regions under study
High avidity to gp120	Not measured in HVTN 505 program Env IgG avidity with low IgA correlated with decreased risk of infection	DNA / MVA containing regimens have high avidity. Other products under study.
CD4+ T cells with polyfunctional response	Different cytokine profile in HVTN 505 vs. RV144	DNA / NYVAC and Ad26/MVA increase prevalence and magnitude of Env specific CD4+ T cells